Athanassiadis D I, Dimopoulos C G, Tsakiris A K, Cokkinos D F, Tourkantonis A A, Toutouzas P K, Boutin B, Guez D
Department of Cardiology and Hypertension, Red Cross Hospital, Athens, Greece.
Am J Cardiol. 1990 May 2;65(17):62H-66H. doi: 10.1016/0002-9149(90)90346-3.
A multicenter study was performed to assess the efficacy and the acceptability of indapamide in hypertensive patients previously untreated, or treated and unsatisfactorily controlled with either angiotensin-converting enzyme (ACE) inhibitor or beta-blocking therapy. Four centers participated in the study, which included patients whose supine diastolic blood pressure was between 95 and 115 mmHg with no treatment (group I, n = 40), those taking captopril (group II, n = 40) or those taking propranolol (group III, n = 40). After a 2-week single-blind placebo run-in period, patients received indapamide either alone (group I) or in combination with the previous therapy (groups II and III) for 4 months. Blood pressure, heart rate, weight, and clinical and biochemical acceptability were measured before and after 2 and 4 months of treatment. At the same time points, quality of life was determined using standardized questionnaires completed by the patient (20 items) and the physician (10 items) and a visual analog scale completed by the patient. In all groups, administration of indapamide induced a clinically and statistically significant reduction in both systolic and diastolic blood pressures in the supine position after 2 months. Indapamide alone controlled blood pressure in 82% of the patients previously untreated, and indapamide in combined therapy controlled blood pressure, respectively, in 67 and 85% of patients previously uncontrolled with ACE inhibitors or beta blockers. In all groups, questionnaires on quality of life showed a progressive and significant improvement in general well-being. After 4 months of treatment, the percentage of improvement in the physician questionnaire was 77.1% in group I, 60.6% in group II and 71.4% in group III.(ABSTRACT TRUNCATED AT 250 WORDS)
一项多中心研究旨在评估吲达帕胺对未经治疗、或接受血管紧张素转换酶（ACE）抑制剂或β受体阻滞剂治疗但控制不佳的高血压患者的疗效和可接受性。四个中心参与了该研究，研究对象包括仰卧位舒张压在95至115 mmHg之间且未接受治疗的患者（I组，n = 40）、服用卡托普利的患者（II组，n = 40）或服用普萘洛尔的患者（III组，n = 40）。经过为期2周的单盲安慰剂导入期后，患者接受单独使用吲达帕胺治疗（I组）或与先前治疗联合使用（II组和III组），为期4个月。在治疗2个月和4个月前后测量血压、心率、体重以及临床和生化可接受性。在相同时间点，使用患者填写的标准化问卷（20项）、医生填写的问卷（10项）以及患者完成的视觉模拟量表来确定生活质量。在所有组中，吲达帕胺给药2个月后，仰卧位收缩压和舒张压均出现临床上和统计学上的显著降低。单独使用吲达帕胺使82%的先前未治疗患者血压得到控制，联合治疗中的吲达帕胺分别使67%和85%先前未被ACE抑制剂或β受体阻滞剂控制的患者血压得到控制。在所有组中，生活质量问卷显示总体幸福感有逐步且显著的改善。治疗4个月后，I组医生问卷的改善百分比为77.1%，II组为60.6%，III组为71.4%。（摘要截断于250字）
